Efficacy and Safety of Bee Venom Therapy (BVT) in Rheumatoid Arthritis: A Comprehensive Review

Abstract

Rheumatoid arthritis (RA) is a chronic, systemic autoimmune inflammatory disease characterised by persistent synovitis, progressive joint destruction, and extra-articular manifestations, affecting approximately 0.5–1% of the global population. Whilst conventional pharmacological management with disease-modifying antirheumatic drugs (DMARDs) and biologic agents has substantially improved clinical outcomes, a meaningful proportion of patients experience incomplete responses, adverse effects, or treatment intolerance, sustaining interest in complementary therapeutic approaches. Bee venom therapy (BVT), encompassing the therapeutic use of crude bee venom, purified venom fractions, or bee venom acupuncture (BVA), has been practised across diverse cultures for millennia and has attracted growing scientific scrutiny over recent decades. Bee venom (Apis mellifera) is a biologically complex mixture of pharmacologically active compounds—including melittin, phospholipase A₂ (PLA₂), apamin, adolapin, and mast cell degranulating peptide—that collectively exert anti-inflammatory, immunomodulatory, analgesic, and potential chondroprotective effects through multiple molecular mechanisms. Preclinical investigations in cellular and animal models of inflammatory arthritis have consistently demonstrated inhibition of nuclear factor kappa-B (NF-κB) signalling, suppression of pro-inflammatory cytokine production, modulation of T-helper cell subset balance, and attenuation of synovial inflammation and cartilage degradation following bee venom administration. Emerging clinical evidence, predominantly from small randomised controlled trials (RCTs) and systematic reviews examining BVA, suggests modest yet promising benefits regarding pain reduction, functional improvement, and disease activity in RA patients. Nevertheless, the clinical evidence base remains constrained by small sample sizes, heterogeneous methodologies, variable venom standardisation, and critical safety concerns centred on anaphylaxis risk. This narrative review critically synthesises available preclinical and clinical evidence for the efficacy and safety of BVT in RA, elucidates the mechanistic underpinnings of venom bioactivity, evaluates safety and regulatory considerations, and identifies priority areas for future investigation.